Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165


Sequence and structural determinants of ligand-dependent alternating access of a MATE transporter.

Jagessar KL, Claxton DP, Stein RA, Mchaourab HS.

Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):4732-4740. doi: 10.1073/pnas.1917139117. Epub 2020 Feb 19.


Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.

Pagel JM, Othus M, Garcia-Manero G, Fang M, Radich JP, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Spellman SR, Confer DL, Chell JW, Brown M, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Bayer RL, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Erba HP, Appelbaum FR.

JCO Oncol Pract. 2020 Jan 27:JOP1900133. doi: 10.1200/JOP.19.00133. [Epub ahead of print]


Ceramide Analogue SACLAC Modulates Sphingolipid Levels and MCL-1 Splicing to Induce Apoptosis in Acute Myeloid Leukemia.

Pearson JM, Tan SF, Sharma A, Annageldiyev C, Fox TE, Abad JL, Fabrias G, Desai D, Amin S, Wang HG, Cabot MC, Claxton DF, Kester M, Feith DJ, Loughran TP.

Mol Cancer Res. 2020 Mar;18(3):352-363. doi: 10.1158/1541-7786.MCR-19-0619. Epub 2019 Nov 19.


Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML.

Zhao C, Jia B, Wang M, Schell TD, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Songdej N, Sivik JM, Hohl RJ, Zeng H, Zheng H.

Br J Haematol. 2020 Mar;188(5):674-684. doi: 10.1111/bjh.16228. Epub 2019 Oct 1.


Preoperative oral antibiotic bowel preparation in elective resectional colorectal surgery reduces rates of surgical site infections: a single-centre experience with a cost-effectiveness analysis.

Vadhwana B, Pouzi A, Surjus Kaneta G, Reid V, Claxton D, Pyne L, Chalmers R, Malik A, Bowers D, Groot-Wassink T.

Ann R Coll Surg Engl. 2020 Feb;102(2):133-140. doi: 10.1308/rcsann.2019.0117. Epub 2019 Sep 11.


Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia.

Barth BM, Wang W, Toran PT, Fox TE, Annageldiyev C, Ondrasik RM, Keasey NR, Brown TJ, Devine VG, Sullivan EC, Cote AL, Papakotsi V, Tan SF, Shanmugavelandy SS, Deering TG, Needle DB, Stern ST, Zhu J, Liao J, Viny AD, Feith DJ, Levine RL, Wang HG, Loughran TP Jr, Sharma A, Kester M, Claxton DF.

Blood Adv. 2019 Sep 10;3(17):2598-2603. doi: 10.1182/bloodadvances.2018021295. No abstract available.


Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells.

Kao LP, Morad SAF, Davis TS, MacDougall MR, Kassai M, Abdelmageed N, Fox TE, Kester M, Loughran TP Jr, Abad JL, Fabrias G, Tan SF, Feith DJ, Claxton DF, Spiegel S, Fisher-Wellman KH, Cabot MC.

J Lipid Res. 2019 Sep;60(9):1590-1602. doi: 10.1194/jlr.RA119000251. Epub 2019 Jul 30.


Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).

Kempin S, Sun Z, Kay NE, Paietta EM, Mazza JJ, Ketterling RP, Frankfurt O, Claxton DF, Saltzman JN, Srkalovic G, Callander NS, Gross G, Tallman MS.

Acta Haematol. 2019;142(4):224-232. doi: 10.1159/000500164. Epub 2019 Jul 23.


The N-terminal domain of an archaeal multidrug and toxin extrusion (MATE) transporter mediates proton coupling required for prokaryotic drug resistance.

Jagessar KL, Mchaourab HS, Claxton DP.

J Biol Chem. 2019 Aug 23;294(34):12807-12814. doi: 10.1074/jbc.RA119.009195. Epub 2019 Jul 9.


Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma.

Spurgeon SE, Sharma K, Claxton DF, Ehmann C, Pu J, Shimko S, Stewart A, Subbiah N, Palmbach G, LeBlanc F, Latour E, Chen Y, Mori M, Hasanali Z, Epner EM.

Br J Haematol. 2019 Sep;186(6):845-854. doi: 10.1111/bjh.16008. Epub 2019 Jun 9.


The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia.

Annageldiyev C, Gowda K, Patel T, Bhattacharya P, Tan SF, Iyer S, Desai D, Dovat S, Feith DJ, Loughran TP Jr, Amin S, Claxton D, Sharma A.

Haematologica. 2020 Mar;105(3):687-696. doi: 10.3324/haematol.2018.212886. Epub 2019 May 23.


Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant-a pilot study.

Pu JJ, Poulose J, Malysz J, Zhu J, Fanburg-Smith JC, Claxton DF, Bayerl MG.

Br J Haematol. 2019 Sep;186(5):e130-e133. doi: 10.1111/bjh.15967. Epub 2019 May 22. No abstract available.


Downregulation of CD73 associates with T cell exhaustion in AML patients.

Kong Y, Jia B, Zhao C, Claxton DF, Sharma A, Annageldiyev C, Fotos JS, Zeng H, Paulson RF, Prabhu KS, Zheng H.

J Hematol Oncol. 2019 Apr 24;12(1):40. doi: 10.1186/s13045-019-0728-3.


Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.

Tan SF, Dunton W, Liu X, Fox TE, Morad SAF, Desai D, Doi K, Conaway MR, Amin S, Claxton DF, Wang HG, Kester M, Cabot MC, Feith DJ, Loughran TP Jr.

J Lipid Res. 2019 Jun;60(6):1078-1086. doi: 10.1194/jlr.M091876. Epub 2019 Apr 8.


Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases.

Cioccio J, Claxton D.

Expert Opin Investig Drugs. 2019 Apr;28(4):337-349. doi: 10.1080/13543784.2019.1584610. Epub 2019 Feb 27. Review.


Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity.

Kokolus KM, Haley JS, Koubek EJ, Gowda R, Dinavahi SS, Sharma A, Claxton DF, Helm KF, Drabick JJ, Robertson GP, Neighbors JD, Hohl RJ, Schell TD.

Oncoimmunology. 2018 Nov 11;8(2):e1539614. doi: 10.1080/2162402X.2018.1539614. eCollection 2019.


Eomes+T-betlow CD8+ T Cells Are Functionally Impaired and Are Associated with Poor Clinical Outcome in Patients with Acute Myeloid Leukemia.

Jia B, Zhao C, Rakszawski KL, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Wang M, Shike H, Bayerl MG, Sivik JM, Schell TD, Drabick JJ, Hohl RJ, Zheng H.

Cancer Res. 2019 Apr 1;79(7):1635-1645. doi: 10.1158/0008-5472.CAN-18-3107. Epub 2019 Feb 1.


Combinatorial Efficacy of Quercitin and Nanoliposomal Ceramide for Acute Myeloid Leukemia.

McGill CM, Brown TJ, Fisher LN, Gustafson SJ, Dunlap KL, Beck AJ, Toran PT, Claxton DF, Barth BM.

Int J Biopharm Sci. 2018;1(1). pii: 106. doi: 10.31021/ijbs.20181106. Epub 2018 Jan 31.


A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.

Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrózek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA.

Blood. 2019 Apr 4;133(14):1548-1559. doi: 10.1182/blood-2018-10-881961. Epub 2019 Jan 18. Erratum in: Blood. 2019 Sep 26;134(13):1111.


Structural Basis of H+-Dependent Conformational Change in a Bacterial MATE Transporter.

Kusakizako T, Claxton DP, Tanaka Y, Maturana AD, Kuroda T, Ishitani R, Mchaourab HS, Nureki O.

Structure. 2019 Feb 5;27(2):293-301.e3. doi: 10.1016/j.str.2018.10.004. Epub 2018 Nov 15.


VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML.

Wang L, Jia B, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Khawaja MR, Sivik J, Han J, Hohl RJ, Zheng H.

Oncoimmunology. 2018 Jul 11;7(9):e1469594. doi: 10.1080/2162402X.2018.1469594. eCollection 2018.


Cryo-EM structure of the benzodiazepine-sensitive α1β1γ2S tri-heteromeric GABAA receptor in complex with GABA.

Phulera S, Zhu H, Yu J, Claxton DP, Yoder N, Yoshioka C, Gouaux E.

Elife. 2018 Jul 25;7. pii: e39383. doi: 10.7554/eLife.39383.


Expression and purification of a functional heteromeric GABAA receptor for structural studies.

Claxton DP, Gouaux E.

PLoS One. 2018 Jul 20;13(7):e0201210. doi: 10.1371/journal.pone.0201210. eCollection 2018.


Engineering of a Polydisperse Small Heat-Shock Protein Reveals Conserved Motifs of Oligomer Plasticity.

Mishra S, Chandler SA, Williams D, Claxton DP, Koteiche HA, Stewart PL, Benesch JLP, Mchaourab HS.

Structure. 2018 Aug 7;26(8):1116-1126.e4. doi: 10.1016/j.str.2018.05.015. Epub 2018 Jul 5.


Sodium and proton coupling in the conformational cycle of a MATE antiporter from Vibrio cholerae.

Claxton DP, Jagessar KL, Steed PR, Stein RA, Mchaourab HS.

Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):E6182-E6190. doi: 10.1073/pnas.1802417115. Epub 2018 Jun 18.


Therapeutic effect of Northern Labrador tea extracts for acute myeloid leukemia.

McGill CM, Tomco PL, Ondrasik RM, Belknap KC, Dwyer GK, Quinlan DJ, Kircher TA, Andam CP, Brown TJ, Claxton DF, Barth BM.

Phytother Res. 2018 Aug;32(8):1636-1641. doi: 10.1002/ptr.6091. Epub 2018 Apr 27.


Therapeutic Effect of Blueberry Extracts for Acute Myeloid Leukemia.

McGill CM, Brown TJ, Cheng YY, Fisher LN, Shanmugavelandy SS, Gustafson SJ, Dunlap KL, Lila MA, Kester M, Toran PT, Claxton DF, Barth BM.

Int J Biopharm Sci. 2018 Jan;1(1). pii: 102. Epub 2018 Jan 2.


Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients.

Jia B, Wang L, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Rizvi S, Shike H, Bayerl M, Schell TD, Hohl RJ, Zheng H.

Blood Cancer J. 2018 Mar 21;8(3):34. doi: 10.1038/s41408-018-0069-4. No abstract available.


Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML.

Rakszawski K, Miki K, Claxton D, Wagner H, Shike H, Mineishi S, Naik S.

Int J Hematol. 2018 Sep;108(3):348-350. doi: 10.1007/s12185-018-2431-5. Epub 2018 Mar 14.


Sprint interval training on the vertical treadmill improves aerobic and anaerobic running performance.

Jordan AR, Claxton D, Purvis A, Barnes A, Fysh M.

J Exerc Rehabil. 2018 Feb 26;14(1):106-112. doi: 10.12965/jer.1835122.561. eCollection 2018 Feb.


Conformational transitions of the sodium-dependent sugar transporter, vSGLT.

Paz A, Claxton DP, Kumar JP, Kazmier K, Bisignano P, Sharma S, Nolte SA, Liwag TM, Nayak V, Wright EM, Grabe M, Mchaourab HS, Abramson J.

Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):E2742-E2751. doi: 10.1073/pnas.1718451115. Epub 2018 Mar 5.


Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia.

Van de Louw A, Desai RJ, Zhu J, Claxton DF.

Leuk Lymphoma. 2018 Oct;59(10):2369-2376. doi: 10.1080/10428194.2018.1435874. Epub 2018 Feb 12.


Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, Howlett C, Skarbnik A, Cheson BD, Zent C, Pu J, Kiselev P, Goy A, Claxton D, Isaac K, Kennard KH, Timlin C, Landsburg D, Winter A, Nasta SD, Bachow SH, Schuster SJ, Dorsey C, Svoboda J, Barr P, Ujjani CS.

Haematologica. 2018 May;103(5):874-879. doi: 10.3324/haematol.2017.182907. Epub 2018 Feb 1.


Orbital Epstein-Barr Virus-Positive Polymorphic B-Cell Lymphoproliferative Disorder in an Apparently Immunocompetent Woman.

Abendroth MD, Bayerl MG, Wilkinson MJ, Claxton DF, Specht CS.

Ocul Oncol Pathol. 2017 Dec;4(1):61-65. doi: 10.1159/000478747. Epub 2017 Aug 11.


Effects of running retraining on biomechanical factors associated with lower limb injury.

Dunn MD, Claxton DB, Fletcher G, Wheat JS, Binney DM.

Hum Mov Sci. 2018 Apr;58:21-31. doi: 10.1016/j.humov.2018.01.001. Epub 2018 Jan 13.


STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia.

Doshi UA, Shaw J, Fox TE, Claxton DF, Loughran TP, Kester M.

Signal Transduct Target Ther. 2017 Oct 27;2:17051. doi: 10.1038/sigtrans.2017.51. eCollection 2017.


Myeloid sarcoma of the thyroid.

Goldenberg D, Joshi M, Malysz J, Claxton D, Cottrill EE.

Ear Nose Throat J. 2017 Dec;96(12):460-461. No abstract available.


Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.

Prabhu VV, Talekar MK, Lulla AR, Kline CLB, Zhou L, Hall J, Van den Heuvel APJ, Dicker DT, Babar J, Grupp SA, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, Khan N, Oster W, Allen JE, El-Deiry WS.

Cell Cycle. 2018;17(4):468-478. doi: 10.1080/15384101.2017.1403689. Epub 2018 Feb 19.


SKI-178: A Multitargeted Inhibitor of Sphingosine Kinase and Microtubule Dynamics Demonstrating Therapeutic Efficacy in Acute Myeloid Leukemia Models.

Hengst JA, Dick TE, Sharma A, Doi K, Hegde S, Tan SF, Geffert LM, Fox TE, Sharma AK, Desai D, Amin S, Kester M, Loughran TP, Paulson RF, Claxton DF, Wang HG, Yun JK.

Cancer Transl Med. 2017 Jul-Aug;3(4):109-121. doi: 10.4103/ctm.ctm_7_17. Epub 2017 Aug 14.


Kinematics and neuromuscular recruitment during vertical treadmill exercise.

Jordan AR, Barnes A, Claxton D, Purvis A, Fysh M.

J Exerc Rehabil. 2017 Jun 30;13(3):307-314. doi: 10.12965/jer.1734916.458. eCollection 2017 Jun.


Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M.

Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Lancet Oncol. 2018 Jul;19(7):e335. Lancet Oncol. 2019 Jun;20(6):e293.


Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.

Zhu L, Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Palmisiano ND, Wang M, Jia B, Bayerl M, Schell TD, Hohl RJ, Zeng H, Zheng H.

J Hematol Oncol. 2017 Jun 19;10(1):124. doi: 10.1186/s13045-017-0486-z.


Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C.

Ann Oncol. 2017 May 1;28(5):1050-1056. doi: 10.1093/annonc/mdx031.


Increased CD13 Expression in Acute Myeloid Leukemia-associated Early Acute Hypoxic Respiratory Failure.

Schneider C, Bayerl M, Boyer C, Desai R, Claxton D, Van de Louw A.

Am J Respir Crit Care Med. 2017 Oct 15;196(8):1077-1080. doi: 10.1164/rccm.201701-0080LE. No abstract available.


Genome-wide mapping of histone H3K9me2 in acute myeloid leukemia reveals large chromosomal domains associated with massive gene silencing and sites of genome instability.

Salzberg AC, Harris-Becker A, Popova EY, Keasey N, Loughran TP, Claxton DF, Grigoryev SA.

PLoS One. 2017 Mar 16;12(3):e0173723. doi: 10.1371/journal.pone.0173723. eCollection 2017.


PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features.

Teye EK, Sido A, Xin P, Finnberg NK, Gokare P, Kawasawa YI, Salzberg AC, Shimko S, Bayerl M, Ehmann WC, Claxton DF, Rybka WB, Drabick JJ, Wang HG, Abraham T, El-Deiry WS, Brodsky RA, J Hohl R, Pu JJ.

Oncotarget. 2017 May 2;8(18):29887-29905. doi: 10.18632/oncotarget.15136.


Therapeutic inhibition of BCL-2 and related family members.

Levy MA, Claxton DF.

Expert Opin Investig Drugs. 2017 Mar;26(3):293-301. doi: 10.1080/13543784.2017.1290078. Epub 2017 Feb 9. Review.


Alternating access mechanisms of LeuT-fold transporters: trailblazing towards the promised energy landscapes.

Kazmier K, Claxton DP, Mchaourab HS.

Curr Opin Struct Biol. 2017 Aug;45:100-108. doi: 10.1016/ Epub 2016 Dec 30. Review.


Chest radiographic and CT findings in hyperleukocytic acute myeloid leukemia: A retrospective cohort study of 73 patients.

Stefanski M, Jamis-Dow C, Bayerl M, Desai RJ, Claxton DF, Van de Louw A.

Medicine (Baltimore). 2016 Nov;95(44):e5285.


Acid ceramidase is upregulated in AML and represents a novel therapeutic target.

Tan SF, Liu X, Fox TE, Barth BM, Sharma A, Turner SD, Awwad A, Dewey A, Doi K, Spitzer B, Shah MV, Morad SA, Desai D, Amin S, Zhu J, Liao J, Yun J, Kester M, Claxton DF, Wang HG, Cabot MC, Schuchman EH, Levine RL, Feith DJ, Loughran TP Jr.

Oncotarget. 2016 Dec 13;7(50):83208-83222. doi: 10.18632/oncotarget.13079.

Supplemental Content

Loading ...
Support Center